Xeris Biopharma Holdings Inc [NASDAQ: XERS] traded at a high on Wednesday, posting a 5.54 gain after which it closed the day’ session at $2.86.
The results of the trading session contributed to over 3684848 shares changing hands. Over the past one week, the price volatility of Xeris Biopharma Holdings Inc stands at 7.88% while the volatility over the past one month is 6.26%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for XERS stock reached $426.14 million, with 138.13 million shares outstanding and 136.40 million shares in the current float. Compared to the average trading volume of 1.40M shares, XERS reached a trading volume of 3684848 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Xeris Biopharma Holdings Inc [XERS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XERS shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XERS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Xeris Biopharma Holdings Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 28, 2024. While these analysts kept the previous recommendation, Craig Hallum raised their target price to Buy. The new note on the price target was released on August 28, 2023, representing the official price target for Xeris Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $4, while Jefferies analysts kept a Buy rating on XERS stock.
The Average True Range (ATR) for Xeris Biopharma Holdings Inc is set at 0.17, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 2.35.
How has XERS stock performed recently?
Xeris Biopharma Holdings Inc [XERS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.33. With this latest performance, XERS shares gained by 27.11% in over the last four-week period, additionally plugging by 29.41% over the last 6 months – not to mention a rise of 36.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 60.98, with the RSI for the last a single of trading hit 63.49, and the three-weeks RSI is set at 59.77 for Xeris Biopharma Holdings Inc [XERS]. The present Moving Average for the last 50 days of trading for this stock 2.50, while it was recorded at 2.66 for the last single week of trading, and 2.31 for the last 200 days.
Xeris Biopharma Holdings Inc [XERS]: Deeper insight into the fundamentals
Xeris Biopharma Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.69 and a Current Ratio set at 2.26.
Insider trade positions for Xeris Biopharma Holdings Inc [XERS]
There are presently around $41.68%, or 43.38%% of XERS stock, in the hands of institutional investors. The top three institutional holders of XERS stocks are: BLACKROCK INC. with ownership of 10.33 million shares, which is approximately 7.3531%. VANGUARD GROUP INC, holding 7.66 million shares of the stock with an approximate value of $$17.23 million in XERS stocks shares; and VANGUARD GROUP INC, currently with $$11.51 million in XERS stock with ownership which is approximately 3.639%.
